Study patients were classified into groups as follows: 1) healthy subjects without glaucoma (WG); 2) glaucoma suspected group (GSG); 3) primary open-angle glaucoma
(POAG); 4) primary angle-closure glaucoma (PACG); and 5) secondary glaucoma (SG).
This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma
, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Richards, PhD, director of the glaucoma research center at the University of Michigan in Ann Arbor, and coauthors examined metformin use and the risk of open-angle glaucoma
(OAG) using data from a large US managed care network from 2001 through 2010.
* Trabeculoplasty, which opens the drainage canals of the eye in patients with open-angle glaucoma
One potential explanation for this significant association of Central Retinal vein occlusion (CRVO) and PEX is the secondary open-angle glaucoma
caused by PEX and the higher levels of IOP associated with PEX compared to simple glaucoma as known risk factors for CRVO.
Over an average of 9.7 years of follow-up, 108 participants developed open-angle glaucoma
. Those who developed the condition were significantly older; more often had high myopia (severe nearsightedness) and were more often male, compared with those who did not.
Eligible patients were aged 40 years and older, did not have primary open-angle glaucoma
(POAG) at baseline, and underwent eye examinations during follow-up.
* Age: For every year someone ages, their chance of progressing increases by 4%, confirming that open-angle glaucoma
is primarily age-related.
LUMIGAN(TM) ophthalmic solution received FDA approval on March 16, 2001 and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma
or ocular hypertension who are intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication.
The Rogers family suffers from a rare subtype of primary open-angle glaucoma
. As in other forms of glaucoma, the fluid in the eye doesn't drain properly.
30, 2019 (HealthDay News) -- Netarsudil ophthalmic solution (0.02 percent; once daily) significantly reduced mean intraocular pressure (IOP) among patients with open-angle glaucoma
or ocular hypertension, according to a study published in the August issue of the American Journal of Ophthalmology.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialisation of first-in-class therapies for the treatment of patients with open-angle glaucoma
, retinal diseases and other diseases of the eye.